Andere Kunden interessierten sich auch für
![Clinician's Manual on Migraine]( "Clinician's Manual on Migraine")
Clinician's Manual on Migraine37,99 €![Netters Innere Medizin]( "Netters Innere Medizin")
Netters Innere Medizin110,00 €![Cardiovascular Safety in Drug Development and Therapeutic Use]( "Cardiovascular Safety in Drug Development and Therapeutic Use")
Cardiovascular Safety in Drug Development and Therapeutic Use74,99 €![Pharmacological Management of Headaches]( "Pharmacological Management of Headaches")
Pharmacological Management of Headaches81,99 €![Psychopharmacology in Oncology and Palliative Care]( "Psychopharmacology in Oncology and Palliative Care")
Psychopharmacology in Oncology and Palliative Care88,99 €![Atrial Fibrillation and Percutaneous Coronary Intervention]( "Atrial Fibrillation and Percutaneous Coronary Intervention")
Atrial Fibrillation and Percutaneous Coronary Intervention66,99 €![Psychopharmacology and Pregnancy]( "Psychopharmacology and Pregnancy")
Psychopharmacology and Pregnancy88,99 €
In this book, the four leading experts on the ACE inhibitors donepezil, galantamine, and rivastigmine and the NMDA receptor antagonist memantine explain the practical pharmacology of these symptomatic drugs with the aim of providing a sound basis for their clinical use in patients with Alzheimer's disease. In addition, an introductory chapter considers the basic theory of pharmacology for Alzheimer's disease and the book closes with an overview of the ways in which symptomatic drugs for dementia are used.
The wide acceptance of the amyloid cascade hypothesis has led to vigorous development of disease-modifying drugs for Alzheimer's disease, such as amyloid vaccinations and gamma- or beta-secretase inhibitors. The failure of clinical trials of these drugs to yield satisfactory results has, however, meant that for the time being patients continue to be treated only with symptomatic drugs. There is accordingly a need to become more proficient in the use of symptomatic medicines, and it is against the background of this quest that Practical Pharmacology for Alzheimer's Disease will be of wide interest.
The wide acceptance of the amyloid cascade hypothesis has led to vigorous development of disease-modifying drugs for Alzheimer's disease, such as amyloid vaccinations and gamma- or beta-secretase inhibitors. The failure of clinical trials of these drugs to yield satisfactory results has, however, meant that for the time being patients continue to be treated only with symptomatic drugs. There is accordingly a need to become more proficient in the use of symptomatic medicines, and it is against the background of this quest that Practical Pharmacology for Alzheimer's Disease will be of wide interest.
"Written by four experts in dementia research, this book describes the pharmacology of the four symptomatic drugs used in the treatment of Alzheimer's disease. It provides an overview of the basic theories of the pharmacology of Alzheimer's disease and the way in which the medications are used for the treatment of dementia. ... book is most suitable for geriatric psychiatrists, geriatric medicine specialists, and neurologists who spend a significant amount of time treating people with Alzheimer's disease and other dementias." (Danielle L. Anderson, Doody's Book Reviews, June, 2016)